Rocket Pharmaceuticals, Inc. Increase (Decrease) in Other Operating Liabilities
Rocket Pharmaceuticals, Inc. (RCKT) reported Increase (Decrease) in Other Operating Liabilities of $69.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $67.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $2.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$1.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was -$81.00K, a 200.00% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $81.00K, a 88.51% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $705.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$57.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $69.00K 10-Q · filed 2026-08-10 | $68.00K derived: sum of 3 quarters · filed 2026-08-10 | $68.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-07 | $1.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.00K derived: sum of 3 quarters · filed 2026-05-07 | -$79.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.00K derived: sum of 2 quarters · filed 2026-02-26 | -$81.00K derived: sum of 3 quarters · filed 2026-08-10 | -$81.00K 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$80.00K derived: sum of 2 quarters · filed 2026-08-10 | -$80.00K 10-Q · filed 2025-11-06 | -$80.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | -$80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$80.00K 10-Q · filed 2026-08-10 | -$80.00K derived: sum of 3 quarters · filed 2026-08-10 | -$79.00K derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $1.00K derived: sum of 3 quarters · filed 2026-05-07 | $2.22M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.22M derived: sum of 3 quarters · filed 2026-02-26 | $81.00K 10-K · filed 2026-02-26 | -$3.67M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.22M derived: sum of 2 quarters · filed 2025-11-06 | $81.00K 10-Q · filed 2025-11-06 | -$1.79M 10-Q · filed 2024-11-07 | $1.51M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $80.00K 10-Q · filed 2025-08-07 | -$1.69M 10-Q · filed 2024-08-06 | $1.51M derived: sum of 3 quarters · filed 2025-08-07 | $1.31M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$2.14M 10-Q · filed 2025-05-08 | -$1.03M 10-Q · filed 2024-05-07 | -$710.00K derived: sum of 2 quarters · filed 2025-05-08 | -$913.00K derived: sum of 3 quarters · filed 2025-05-08 | -$716.00K derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.23M derived: sum of 2 quarters · filed 2025-02-27 | $1.43M derived: sum of 3 quarters · filed 2025-02-27 | $705.00K 10-K · filed 2025-02-27 | $341.00K 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$6.00K derived: sum of 2 quarters · filed 2024-11-07 | -$726.00K 10-Q · filed 2024-11-07 | -$740.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$523.00K 10-Q · filed 2024-08-06 | -$537.00K derived: sum of 3 quarters · filed 2025-02-27 | -$551.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$720.00K 10-Q · filed 2024-05-07 | -$734.00K derived: sum of 2 quarters · filed 2025-02-27 | -$748.00K derived: sum of 3 quarters · filed 2025-02-27 | -$762.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$28.00K derived: sum of 2 quarters · filed 2025-02-27 | -$42.00K derived: sum of 3 quarters · filed 2025-02-27 | -$57.00K 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$28.00K derived: sum of 2 quarters · filed 2023-11-07 | -$43.00K 10-Q · filed 2023-11-07 | -$57.00K derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$29.00K 10-Q · filed 2023-08-09 | -$43.00K derived: sum of 3 quarters · filed 2024-02-27 | -$56.00K derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$15.00K 10-Q · filed 2023-05-05 | -$29.00K derived: sum of 2 quarters · filed 2024-02-27 | -$42.00K derived: sum of 3 quarters · filed 2024-02-27 | -$57.00K derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$27.00K derived: sum of 2 quarters · filed 2024-02-27 | -$42.00K derived: sum of 3 quarters · filed 2024-02-27 | -$56.00K 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$28.00K derived: sum of 2 quarters · filed 2022-11-04 | -$42.00K 10-Q · filed 2022-11-04 | $71.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$29.00K 10-Q · filed 2022-08-09 | $84.00K derived: sum of 3 quarters · filed 2023-02-28 | $84.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$14.00K 10-Q · filed 2022-05-06 | $99.00K derived: sum of 2 quarters · filed 2023-02-28 | $99.00K derived: sum of 3 quarters · filed 2023-02-28 | $99.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $113.00K derived: sum of 2 quarters · filed 2023-02-28 | $113.00K derived: sum of 3 quarters · filed 2023-02-28 | $113.00K 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |